

## Draft Agenda

### 70<sup>th</sup> meeting of the Member State Committee

10-12 June 2020  
(ECHA Conference Centre)  
Web conference

10 June: starts at 10:00 am  
12 June: ends at 16:30

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

MSC/A/070/2020  
*For adoption*

Item 3 – Declaration of specific interests to items on the Agenda

Item 4 – Administrative issues

- Outlook for MSC-70bis and MSC-71
- Presentation on modules and use of Interact tool

*For information*

Item 5 – Minutes of the MSC-69

- Draft minutes of MSC-69

MSC/M/69/2020  
*For adoption*

Item 6 – Substance evaluation

*Closed session for 6.1*

#### 1. Written procedure plans on seeking agreement on draft decisions on substance evaluation

1.1. Introduction to the on substance evaluation when amendments were proposed by MS-CA's/ECHA and preliminary discussion (*Closed session*):

Case	Substance	EC/List No/ Documents <sup>1</sup>
------	-----------	---------------------------------------

<sup>1</sup> Most are room documents

SEV-2-FR-013/2013	Tris(4-nonylphenyl, branched) phosphite	701-028-2 ECHA/MSC-70/2020/006-7
SEV-BE-008/2018	Amphoteric Fluorinated Surfactant	ECHA/MSC-70/2020/008-9
SEV-ES-010/2018	3-ethoxy-1,1,1,2,3,4,4,5,5,6,6,6-dodecafluoro- 2-(trifluoromethyl)hexane	435-790-1 ECHA/MSC-70/2020/010-11
SEV-2-AT-002/2012	Tris(2-ethylhexyl) benzene-1,2,4-tricarboxylate	222-020-0 ECHA/MSC-70/2020/012

***For information and discussion***

## 1.2. Written procedure timing plans

***For information***

## 2. Seeking agreement on draft decisions when amendments were proposed by MS-CA's/ECHA (*Session 2, closed*)

No cases

***[For agreement]***

## 3. General topics

None

***[For information]***

## Item 7 – Dossier evaluation

***Closed session for 7.1 and partly for 7.3***

## 1. Written procedure plans on seeking agreement on draft decisions on dossier evaluation

**1.1. Introduction to the PfAs and Registrants' comments on draft decisions on compliance checks and testing proposals when amendments were proposed by MS-CA's and preliminary discussion (*Closed session*)**

### **Compliance checks<sup>2</sup>**

MSC code	Substance name	EC/List No.
CCH-038/2020	Tris(2-ethylhexyl) benzene-1,2,4-tricarboxylate	222-020-0
CCH-051/2020	2,2'-azobis[2-methylbutyronitrile]	236-740-8

***For information and discussion***

## 1.2. Introduction of the written procedure timing plans

***For information***

## 2. Seeking agreement on draft decisions on compliance checks and testing proposal examinations when amendments were proposed by MS-CA's (*Session 2, closed*)

No cases

***[For agreement]***

## 3. General topics

1) Dossier evaluation *in vivo* comet assay requests in case of concerns for both chromosomal aberrations and gene mutation (*Partly closed session*)

ECHA/MSC-70/2020/001 & 002

***For discussion and agreement***

2) Invitation to discuss a decision tree for terrestrial endpoints under dossier evaluation

<sup>2</sup> Case specific documents are available in MSC S-Circabc folder 05. Dossier evaluation 1. Compliance check draft decisions

*For information*

**Item 8 – SVHC identification - Seeking agreement on Annex XV proposals for identification of SVHC**

*Start time: Day 1 morning*

**1. Written procedure report on seeking agreement on identification of SVHC<sup>3</sup>**

ECHA/MSC-70/2020/003

*For information*

**2. Seeking agreement on Annex XV proposals for identification of SVHC**

<b>Substance name</b>	<b>EC/List No.</b>	<b>Documents</b>
Resorcinol	203-585-2	ECHA/MSC-70/2020/004-005, ECHA/MSC-70/2020/013

*For discussion and agreement*

**Item 9 – ECHA’s recommendations of priority substances to be included in Annex XIV and opinion of MSC**

Invitation for volunteers for rapporteurship

*For information*

**Item 10 – Opinion of MSC on ECHA’s draft update of the Community Rolling Action Plan (CoRAP 2021-2023)**

Invitation for volunteers for rapporteurship

*For information*

**Item 11 – Any other business**

1. Update on appeals and court cases of relevance to MSC

*(Partly closed session)*

*For information*

2. Suggestions from members

*For information*

**Item 12 – ECHA’s Executive Director address to MSC**

*For information*

**Item 13 – Adoption of main conclusions and action points**

- Table with conclusions and action points from MSC-70

*For adoption*

**INFORMATION DOCUMENTS**

Information documents are not allocated a specific agenda time but the documents are available on MSC CIRCABC before the meeting. Based on the listed documents and the meeting agenda, if any MSC member considers that information documents may merit a discussion under any agenda point, they should inform MSC Secretariat.

<sup>3</sup> List of SVHC proposals agreed by MSC in written procedure in advance of MSC-70 meeting is available at the end of the agenda as an appendix.

- Status report on on-going substance evaluation work (presentation slides)
- Status report on on-going dossier evaluation work (presentation slides)

**APPENDIX to the MSC-70 agenda**

**List of SVHC proposals agreed by MSC in written procedure in advance of the MSC-70 meeting:**

<b>Substance name</b>	<b>EC/List No.</b>	<b>CAS No.</b>
Butyl 4-hydroxybenzoate	202-318-7	94-26-8
Dibutylbis(pentane-2,4-dionato-O,O')tin	245-152-0	22673-19-4